Possible approaches to this problem include surgical debridement, vacuum-assisted closure, systemic antibiotics, and odor-controlling and medicated dressings; however, the outcomes are often ...

MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced ...

MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced the publication of a peer-reviewed post ...

Vericel also holds an exclusive license for North American rights to NexoBrid (anacaulase-bcdb), a biological orphan product containing proteolytic enzymes, which is indicated for eschar removal ...

EscharEx has shown clinical advantages over the leading enzymatic debridement product and targets ... is indicated for the enzymatic removal of eschar in thermal burns and is marketed in the ...